JAK2 and acquired polycythemia vera: More extensive use of the JAK1/JAK2 inhibitor ruxolitinib is associated with a greater risk of mycobacterial infections (Mycobacterium tuberculosis and atypical mycobacterial infections) in the treatment of patients with myelofibrosis and polycythemia vera (64, 65).